Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label trial of Lu-PSMA plus SABR versus SABR alone in oligometastatic prostate cancer
MOH_2023-10-18_012945Phase 2Not yet recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Oct 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa) (2 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Progression-free survival. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2023-10-18_012945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-18_012945.